In the lactating mammary gland, the plasma membrane calcium ATPase2 (PMCA2) transports milk calcium. Its expression is activated in breast cancers, where high tumor levels predict increased mortality. We find that PMCA2 expression correlates with HER2 levels in breast cancers and that PMCA2 interacts with HER2 in specific actin-rich membrane domains. Knocking down PMCA2 increases intracellular calcium, disrupts interactions between HER2 and HSP-90, inhibits HER2 signaling, and results in internalization and degradation of HER2. Manipulating PMCA2 levels regulates the growth of breast cancer cells, and knocking out PMCA2 inhibits the formation of tumors in mouse mammary tumor virus (MMTV)-Neu mice. These data reveal previously unappreciated molecular interactions regulating HER2 localization, membrane retention, and signaling, as well as the ability of HER2 to generate breast tumors, suggesting that interactions between PMCA2 and HER2 may represent therapeutic targets for breast cancer.
In the lactating mammary gland, the plasma membrane calcium ATPase2 (PMCA2) transports milk calcium. Its expression is activated in breast cancers, where high tumor levels predict increased mortality. We find that PMCA2 expression correlates with HER2 levels in breast cancers and that PMCA2 interacts with HER2 in specific actin-rich membrane domains. Knocking down PMCA2 increases intracellular calcium, disrupts interactions between HER2 and HSP-90, inhibits HER2 signaling, and results in internalization and degradation of HER2. Manipulating PMCA2 levels regulates the growth of breast cancer cells, and knocking out PMCA2 inhibits the formation of tumors in mouse mammary tumor virus (MMTV)-Neu mice. These data reveal previously unappreciated molecular interactions regulating HER2 localization, membrane retention, and signaling, as well as the ability of HER2 to generate breast tumors, suggesting that interactions between PMCA2 and HER2 may represent therapeutic targets for breast cancer.
calcium pumps | ErbB2 | receptor internalization | HSP-90 | epidermal growth factor receptor P lasma membrane calcium ATPases (PMCAs) are a family of ion pumps that transport calcium out of cells and maintain low resting intracellular calcium levels (1) (2) (3) . PMCA2 (gene symbol Atp2b2) is highly expressed in the apical membrane of mammary epithelial cells only during lactation, where it has been shown to transport calcium into milk (4) (5) (6) . After weaning, PMCA2 expression rapidly decreases, contributing to the initiation of programmed cell death and mammary gland involution (7, 8) . PMCA2 is also expressed in breast cancers (8) (9) (10) , and high levels of tumor PMCA2 expression predict increased mortality in patients (8) .
Approximately 25-30% of invasive breast cancers overexpress human epidermal growth factor receptor 2 (HER2) as a result of amplification of the ERBB2 kinase gene (11) (12) (13) , and overexpression of HER2 causes breast tumors in mouse mammary tumor virus (MMTV)-Neu transgenic mice (14) . HER2 functions as a heterodimer with other ERBB family members, most commonly pairing with EGFR or human epidermal growth factor receptor 3 (HER3) in breast cancers (11, 13) . For reasons that remain poorly understood, in contrast to other ERBB family members, which are internalized and degraded after stimulation, HER2 remains on the cell surface and continues to signal for prolonged periods (12, 15) .
In this study, we describe a previously unrecognized function for PMCA2: supporting active HER2 signaling and HER2-mediated tumor formation. Our data suggest that PMCA2 interacts with HER2 within specific membrane domains and is required for HER2 expression, membrane retention, and signaling.
Results PMCA2 and HER2 Are Coexpressed in Breast Cancers. PMCA2 levels correlate with HER2 in breast tumors (8) . To further explore potential interactions between PMCA2 and HER2, we analyzed their expression in a previously reported tissue microarray consisting of 652 breast cancers with a median 9 y of clinical follow-up (8, 16) . Patients with the highest quartiles of both PMCA2 and HER2 expression had significantly shorter survival than patients whose tumors expressed lower levels of either protein (Fig. 1A) . We also examined ATP2B2 (PMCA2) and ERBB2 (HER2) mRNA levels in a gene array study of a different cohort of 204 breast cancers of mixed subtypes (15% basal, 24% luminal A, 25% luminal B, 16% HER2, 20% normal-like) (17) . As shown in Fig. 1B , there was a positive but bimodal correlation between the expression of the ATP2B2 and ERBB2 genes: one group expressed low levels of both genes, and another group had higher levels of both. We next performed immunofluorescence staining for both proteins in breast cancers. PMCA2 and HER2 were expressed at very low levels in wild-type mouse luminal epithelial cells (Fig. S1 ), but at much higher levels in hyperplasia and mammary tumors from MMTV-Neu mice (overexpressing HER2/Neu), where they colocalized at the cell membrane (Fig. S1) . Similarly, in a series of 20 human ductal carcinoma in situ (DCIS) lesions, we found that all the HER2-positive, but none of the HER2-negative, samples expressed PMCA2. In HER2-positive DCIS, PMCA2 colocalized with HER2 at the cell membrane (Fig. 1C) .
PMCA2 Influences HER2 Signaling. We next knocked down PMCA2 expression in SKBR3 and BT474 cells, two HER2-positive breast cancer cell lines. This reduced total HER2 levels and greatly decreased pHER2 levels (Fig. 1D) . Total EGFR levels were essentially unchanged, but pEGFR, total HER3, and pHER3 levels were Significance Unlike other ErbB receptors, human epidermal growth factor receptor 2 (HER2) does not generally become internalized after activation but, instead, remains on the cell surface to signal for prolonged periods. This property is thought to contribute to HER2's ability to transform cells when overexpressed. The current study demonstrates that HER2's resistance to endocytosis depends on the presence of the calcium pump, plasma membrane calcium ATPase2 (PMCA2), in specific membrane signaling domains in which intracellular calcium must be kept low to permit continued HER2 biochemical signaling. The dramatic reduction of mammary tumors in mouse mammary tumor virus (MMTV)-Neu mice in the absence of PMCA2 demonstrates its importance in supporting the development of breast tumors. Therefore, targeting interactions between PMCA2 and HER2 may offer therapeutic strategies for breast cancer. significantly reduced. In addition, knocking down PMCA2 reduced phosphorylated protein kinase B (pAKT) levels (Fig. 1D) . Immunofluorescence staining for pHER2 and pAKT was prominent in control SKBR3 cells but greatly reduced in PMCA2KD SKBR3 cells (Fig. 1E ). We measured AKT activity by assessing the localization of FOXO1 and the expression of a luciferase reporter gene regulated by FOXO1 binding (18) . PMCA2KD cells displayed nuclear staining for FOXO1 and elevated FOXO1-luciferase activity, confirming reductions in AKT bioactivity ( Fig. 1 F-H) .
We treated SKBR3-PMCA2KD cells with epidermal growth factor (EGF) or neuregulin 1 (NRG1) to examine the effects of PMCA2 on HER2/EGFR or HER2/HER3 heterodimers, respectively. As shown in Fig. S1 , basal levels of pHER2 and pEGFR were greatly reduced in PMCA2KD cells, and although they increased in response to EGF, they did not even reach the control baseline levels. In contrast, PMCA2KD cells showed a robust induction of EGFR phosphorylation, although pEGFR levels decreased more rapidly after stimulation and AKT phosphorylation was reduced. Knocking down PMCA2 also blunted responses to NRG1 (Fig. S1 ). As previously reported, acute treatment of the control SKBR3 cells with NRG1 actually initially decreased pHER2 levels, followed by a sustained increase between 2 and 180 min (19) . Knocking down PMCA2 resulted in little change in pHER2 in response to NRG1 and blunted the increase and significantly shortened the duration of HER3 and AKT phosphorylation.
Next, we compared global changes in gene expression caused by knocking down PMCA2 with those induced by knocking down HER2 ( Fig. S2; HER2KD cells) . We defined 853 transcripts that were significantly altered more than twofold in either direction [P < 0.05; false discovery rate (FDR) < 0.05] in PMCA2KD cells and 840 transcripts that were changed in HER2KD cells. There was significant concordance between the changes in gene expression, with 579 (68%) of the genes altered in PMCA2KD cells also changed in HER2KD cells (Fig. S2 ). This is further illustrated by a heat map (Fig. S2 ) comparing the relative changes in all 1,127 transcripts up-regulated or down-regulated in either cell line. Functional annotation of the changes in gene expression demonstrated a strong correlation with ERBB2 signaling, and the altered genes were enriched for cancer-associated transcripts (Fig. S2 ). Changes in the 85 genes in the "advanced malignant tumor" category were remarkably similar between the two knockdown cell types (Fig. S2) . Using quantitative reverse transcription-PCR (QPCR), we validated changes in the expression of seven cancer-associated genes that were altered in both cell lines (Fig. S2 ). These data support the view that PMCA2 influences HER2-dependent gene networks.
PMCA2 Regulates Breast Cancer Cell Growth and Tumor Formation.
Knocking down PMCA2 inhibited the proliferation of SKBR3 cells, reducing BrdU incorporation by 62 ± 6% ( Fig. 2 A and B) . Baseline apoptosis tended to increase in PMCA2KD cells, although these differences were not statistically significant (Fig.  2C) . However, previous studies had suggested that PMCA2 protects against calcium-induced cell death (8) , and apoptosis rates were increased when PMCA2KD cells were exposed to high extracellular calcium ± ionomycin (Fig. 2C) .
We overexpressed PMCA2 in T47D cells, which normally display low levels of PMCA2 and HER2. This substantially increased HER2, pHER2, and pAKT levels ( Fig. 2 D and E) . When we grew T47D cells as xenografts in immunocompromised mice, overexpression of PMCA2 increased the incidence and shortened the latency of tumor development (Fig. 2F) . The growth rate of tumors overexpressing PMCA2 was increased in comparison with control tumors, which correlated with an increase in BrdU incorporation and a decrease in apoptosis in PMCA2-overexpressing T47D tumors (Fig. 2 G-I) .
Next, we crossed MMTV-Neu mice with Dfw-2J mice, which harbor a null mutation of the Atp2b2 (PMCA2) gene (6, 8, 20) . The loss of PMCA2 significantly reduced tumor incidence and prolonged tumor latency (Fig. 2J) . Furthermore, loss of PMCA2 inhibited the development of premalignant alveolar hyperplasia in MMTV-Neu;PMCA2-null mice compared with MMTV-Neu mice, in which it was universally present (Fig. 2K) . Tumors that eventually developed in the MMTV-Neu;PMCA2-null mice demonstrated lower rates of BrdU incorporation (Fig. 2L) . Apoptosis, as assessed by TUNEL staining, was negligible in both tumor types.
PMCA2 Regulates HER2 Localization and Membrane Retention. Confocal microscopy demonstrated that PMCA2 and HER2 colocalize within membrane structures protruding from the apical aspect of SKBR3 cells (Fig. 3A) . A similar, although not as pronounced, pattern of colocalization was noted when we transiently expressed GFP-tagged PMCA2 in MCF10A cells that overexpressed wild-type HER2 (Fig. 3A) . Costaining for actin (phalloidin) with HER2 and PMCA2 demonstrated that these structures were actin-rich (Fig.  S3 ). EGFR and HER3 also colocalized with HER2 within similar structures, suggesting they are nodes for HER2 signaling (Fig. S3) . To determine whether PMCA2 and HER2 interact within a common complex, we performed coimmunoprecipitation (IP) experiments. As shown in Fig. 3B , IP of PMCA2 from SKBR3 cells pulled down HER2 and IP of HER2 pulled down PMCA2. Similar results were obtained when we performed co-IP experiments using protein extracts prepared from MMTV-Neu tumors (Fig. 3C) .
We next examined immunofluorescence for HER2, EGFR, and HER3 in PMCA2KD cells. HER2 and EGFR became more diffusely distributed over the surface of these cells, whereas HER3 staining was dramatically reduced (Fig. 3D and Fig. S3 ). Knocking down PMCA2 also caused effacement of the actin-rich protrusions, although HER2 still appeared to colocalize with actin ( Fig. 3D and  Fig. S3 ). The change in the membrane structures was obvious using scanning and transmission electron microscopy. As shown in Fig.  3E , we observed complex membrane structures protruding from the surface of control cells, but not from the knockdown cells. Thus, PMCA2 is necessary for the organization of actin-rich membrane domains that include HER2, EGFR, and HER3.
Unlike other ErbB family members, HER2 remains on the cell surface after activation (12) . Consistent with this, acute treatment of control SKBR3 cells with EGF or NRG1 increased the localization of HER2 to membrane protrusions, but caused internalization of EGFR and HER3 (Fig. 3F) . In contrast, treatment of PMCA2KD cells with EGF or NRG1 caused internalization of HER2 and its colocalization with EGFR, HER3, and the endosomal marker rab5 within intracellular vesicles (Fig. 3 F and H) . This was also true for the phosphorylated receptors (Fig. S3) . To quantify cell surface HER2, we biotinylated cell surface proteins, IPed biotin, and measured HER2 in the immunoprecipitate from control and PMCA2KD cells. As shown in Fig. 3G , there was a dramatic reduction in biotinylated cell surface HER2 in knockdown cells at baseline or in response to acute treatment with EGF.
However
Internalization and degradation of HER2 can occur after its polyubiquitination by the E3 ubiquitin ligase, c-Cbl (21) (22) (23) . In control cells, c-Cbl and HER2 do not colocalize after stimulation with EGF or NRG1, but in PMCA2KD cells, c-Cbl becomes colocalized with HER2 at the cell surface and within the cytoplasm after receptor stimulation (Fig. 3I and Fig. S3 ). Using a monoclonal antibody (FK2) that recognizes polyubiquitin complexes, we also costained for HER2, pHER2, and polyubiquitin residues. FK2 staining colocalized with HER2 and pHER2 in perinuclear vesicles after EGF treatment in the knockdown cells, but not in control cells (Fig. 3J and Fig. S3 ). We observed similar patterns for p62, which binds to polyubiquitinated proteins localized to autophagosomes (Fig. S3) . Last, IP for polyubiquitin complexes and blotting for HER2 demonstrated increased ubiquitination of HER2 in the knockdown cells (Fig. S3) . These data suggest that PMCA2 prevents ubiquitination and removal of HER2 from the cell surface.
Increased Intracellular Calcium Inhibits HER2 Signaling and Stimulates HER2 Internalization. Intracellular calcium levels in PMCA2KD cells were 5.4-fold higher than in control cells (Fig. 4A) , suggesting that PMCA2 might support HER2 signaling by lowering cytoplasmic calcium. To test this idea, we exposed SKBR3 cells to high extracellular calcium concentrations and ionomycin to increase intracellular calcium levels. This antagonized interactions between HER2 and PMCA2, as reflected by a reduction in the amount of PMCA2 pulled down by IP of HER2 (Fig. 4B) . Treatment with calcium and ionomycin also reduced pHER2, pEGFR, pHER3, and pAKT levels (Fig. 4C ) and caused nuclear translocation of FOXO1 (Fig. S4 ). Ionomycin and extracellular calcium flattened the actin-rich membrane protrusions (Fig. 4D ) and led to costaining for HER2 and actin within the cell (Fig. 4D) . Internalization of HER2 was more obvious when SKBR3 cells were pretreated with 10 mM calcium and ionomycin followed by 2 h exposure to EGF. As seen in Fig. 4E , this led to internalization and colocalization of HER2 with EGFR, and HER2 with FK2 staining in intracellular vesicles (Fig. 4E ). HER2 and HER3 were also internalized in response to NRG1, but there was less colocalization of HER2 with HER3 (Fig. 4E) . Finally, acute (16 h) exposure to calcium and ionomycin reduced membrane HER2 levels, as assessed by the cell surface biotinylation assay, although not to the same degree as chronic knock down of PMCA2 (Figs. 4F and 3G) .
To test whether the calcium pumping function of PMCA2 is required for HER2 signaling, we used a doxycycline-inducible system to overexpress, in T47D cells, equal amounts of wild-type PMCA2 or a mutant form (PMCA2T692K) that has been shown to traffic normally, but that cannot pump calcium (24) (Fig. 4 G and H  and Fig. S4 ). As expected, overexpression of wtPMCA2, but not PMCA2T692K, reduced intracellular calcium concentrations (Fig.  4I) . Expression of wtPMCA2 increased HER2, pHER2, and pAKT levels, and although expression of PMCA2T692K increased total HER2 levels, it did not activate HER2/AKT signaling ( Fig. 4H and  Fig. S4 ). Overexpression of wtPMCA2, but not PMCA2T692K, stimulated proliferation and inhibited apoptosis in T47D cells (Fig.  4 J and K) . Thus, PMCA2 must transport calcium to influence HER2 signaling.
PMCA2 Promotes Interactions Between HER2 and HSP-90. Interactions with HSP-90 stabilize HER2 at the cell membrane, prevent its internalization, and facilitate HER2 signaling (12, (25) (26) (27) (28) . Therefore, we examined the previously described tissue microarray (TMA) and microarray databases and found that HSP-90 expression correlates with PMCA2 expression in human breast cancers at both a protein (Fig. 5A) and mRNA (Fig. 5B) level. Similar to PMCA2 and HER2 (Fig. 1B) , PMCA2 and HSP-90 mRNA levels were distributed in a bimodal pattern, suggesting tumors tended to have either low or high levels of both transcripts. Likewise, a χ analysis of the TMA data demonstrated a statistically significant clustering of tumors into groups with either high or low levels of both HSP-90 and PMCA2 staining. We found HER2 and HSP-90 colocalized in membrane protrusions in SKBR3 cells (Fig. 5C ) (12, 26) , but their colocalization was abolished in PMCA2KD cells (Fig. 5C ). Stimulation with EGF or NRG1 accentuated colocalization between HSP-90 and HER2 in control cells, but caused internalization of HER2 and loss of colocalization with HSP-90 in PMCA2KD cells (Fig. 5C) . In control cells, IP of HSP-90 pulled down HER2 (Fig. 5D) . However, although total HSP-90 levels did not change in the PMCA2KD cells, the ability to co-IP HER2 with HSP-90 was greatly diminished (Fig. 5D) . Interactions between HSP-90 and HER2 were also sensitive to intracellular calcium, as treatment with 10 mM calcium and ionomycin led to loss of their colocalization by immunofluorescence and reduced their co-IP (Fig. S5) . Finally, knocking down HSP-90 in SKBR3 cells reduced HER2 and pHER2 levels as anticipated (Fig. 5E) . However, it also reduced PMCA2 expression and increased intracellular calcium levels (Fig. 5F ). Reductions in HSP-90 led to internalization and ubiquitination of HER2 and its intracellular colocalization with EGFR and HER3 after stimulation with EGF or NRG1 (Fig. 5 G and H) . These data suggest that PMCA2 is required for HSP-90 to interact with cell surface HER2.
Discussion
We find that PMCA2 colocalizes with HER2 in human DCIS lesions and that expression of PMCA2 and HER2 correlate with each other in breast cancers from patients. In breast cancer cells, we find that PMCA2 interacts with HER2 within actin-rich membrane microdomains, and that PMCA2 is required for proper maintenance of these domains, localization of HER2 to these structures, interactions between HER2 with HSP-90, and the ability of HER2 to remain on the cell surface and signal after activation by either EGF or NRG1 (Fig. 5I) . Finally, we find that manipulating PMCA2 levels alters the proliferation and apoptosis of breast cancer cells and that knocking out PMCA2 inhibits the development of hyperplasia and tumors in MMTV-Neu mice. Therefore, we propose that interactions between PMCA2 and HER2 regulate the cell surface stability of HER2, its biochemical signaling, and its ability to promote malignant behavior.
Transformed cells remodel intracellular calcium homeostasis to support malignant behavior, and our experiments highlight the importance of PMCAs in this process (29) (30) (31) . We find that PMCA2 regulates HER2 function, in part, through its ability to lower intracellular calcium. Knocking down PMCA2 raised intracellular calcium levels and inhibited HER2 signaling in SKBR3 cells, whereas the expression of wild-type PMCA2, but not a mutant PMCA2 incapable of transporting calcium, lowered intracellular calcium and activated HER2 signaling in T47D cells. Furthermore, increasing intracellular calcium with a calcium ionophore inhibited HER2 signaling and promoted its internalization and ubiquitination. Therefore, PMCA2 appears to support HER2-mediated transformation by maintaining low intracellular calcium concentrations in the microenvironment surrounding a membranesignaling complex that includes HER2, HER3, EGFR, and HSP-90.
Receptor internalization followed by recycling or degradation is important for modulating receptor tyrosine kinases (12, 15) . Unlike other ErbB family receptors, HER2 resists internalization and degradation and remains at the cell surface, where it can continue to signal for prolonged periods (12, 32) . Several groups have reported that HER2 resides within microvillus-like membrane protrusions, and Hommelgaard and colleagues hypothesized that these structures support the retention of HER2 on the cell surface (33) (34) (35) (36) . Previous experiments also showed that interactions with HSP-90 are important for HER2 stabilization within membrane protrusions and its resistance to internalization (12, 26) . Thus, it is noteworthy that PMCA2 levels correlate with HSP-90 levels in human tumors and that knockdown of PMCA2 is associated with decreased interactions between HSP-90 and HER2, the internalization of HER2, and the disruption of the membrane protrusions. HER2 localization and signaling appear to be intimately related to the presence of protruding membrane microdomains, and our results do not fully distinguish whether internalization of HER2 is caused directly from loss of its interactions with PMCA2, or secondarily from elevated intracellular calcium and/or the disruption of the membrane domains. We envision that HER2 is actively retained within membrane signaling domains as a result of complex interactions with PMCA2, scaffolding proteins, and the actin cytoskeleton (37, 38) . Furthermore, PMCA2 may be recruited to these signaling domains to prevent their disruption by intracellular calcium and/or to inhibit calcium-dependent movement of HER2 out of these macromolecular assemblies and into an endocytic pathway normally used by other ErbB family members (Fig. 5I) (38) (39) (40) .
In summary, our findings demonstrate that PMCA2 is vital for the localization of HER2 and its partners, EGFR and HER3, to active membrane signaling domains. PMCA2 helps prevent HER2 internalization after receptor stimulation and sustains downstream signal transduction. Genetic manipulation of PMCA2 regulates the growth of breast cancers in vivo, and PMCA2 predicts outcome in human patients (8) . Targeting PMCA2-HER2 interactions may offer novel opportunities for therapeutic development.
Methods
Knockdown Cell Lines. Stable cell lines expressing shRNA directed against ATP2B2, HSP-90, and ERBB2 were generated by transducing cells with commercially prepared lentiviruses: PMCA2 (sc-42598) and HSP-90α/β (SC-35608-V) from Santa Cruz and HER2 (318-328) from AMSbio.
PMCA2 Overexpression. T47D cell lines overexpressing wtPMCA2 were previously described (8) . The Quick Change Site-Directed Mutagenesis Kit (Agilent) was used to change nucleotide 2075 of the mouse pT-REx-PMCA2w/b construct (8) from C to A, creating the T692K mutation (24) . The sequence of the mutant construct was verified on both strands, and T47D cells were sequentially transfected with pcDNA6-TR (tetracycline-regulated repressor; Life Technologies) and the tet-regulated WT PMCA2, T692KPMCA2, or control expression vector. Expression was induced with 50 μg/mL doxycycline.
Tissue Microarray. The breast carcinoma tissue microarray (YTMA49) consisted of 652 primary breast cancer specimens retrospectively obtained from 1953 to 1983, as previously described (8) .
Transgenic and Mutant Mice. We generated MMTV-Neu/PMCA2 dfw-2J/dfw-2J and control MMTV-Neu/PMCA2 wt/wt mice and followed them weekly for the pres- Statistics. Statistical analyses were performed with Prism 6.0 (GraphPad Software).
